Search

Your search keyword '"TCR gamma chain gene"' showing total 2 results
Start Over Descriptor "TCR gamma chain gene"
2 results on '"TCR gamma chain gene"'

1. Gamma-delta hepatosplenic T-cell lymphoma. Description of a case with immunophenotypic and molecular follow-up successfully treated with chemotherapy alone.

Author

Moleti, Maria Luisa, Testi, Anna Maria, Giona, Fiorina, Amendola, Angela, Palumbo, Giovanna, Uccini, Stefania, Starza, Irene Della, de Propris, Maria Stefania, Guarini, Anna, and Foà, Robin

Subjects
*LYMPHOMAS, *ANTINEOPLASTIC agents, *CANCER chemotherapy, *DRUG therapy, *RETICULOENDOTHELIAL granulomas, *ETOPOSIDE, *ONCOLOGY
Abstract

This study hereby reports the case of a 19-year old boy with a gamma-delta hepatosplenic T-cell lymphoma (HSTCL). Initial therapy consisted of four cycles of the IEV (Ifosphamide, Epirubicin and Etoposide) scheme. Further treatment strategy was then adapted according to minimal residual disease monitoring by immunophenotypic and T-cell receptor gamma chain gene evaluation. The patient remains in complete clinical, immunological and molecular remission and in good clinical conditions 48 months after diagnosis and 40 months after stopping therapy. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

2. Gamma-delta hepatosplenic T-cell lymphoma. Description of a case with immunophenotypic and molecular follow-up successfully treated with chemotherapy alone

Author

Anna Guarini, Fiorina Giona, Anna Maria Testi, Irene Della Starza, Maria Luisa Moleti, Stefania Uccini, Robin Foà, Giovanna Palumbo, Maria Stefania De Propris, and Angela Amendola

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Pathology, Neoplasm, Residual, Hepatosplenic T-cell lymphoma, medicine.medical_treatment, Lymphoma, T-Cell, chemotherapy, Sensitivity and Specificity, Gastroenterology, Immunophenotyping, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Gamma-delta hepatosplenic T-cell lymphoma, TCR gamma chain gene, Initial therapy, Etoposide, Chemotherapy, business.industry, Remission Induction, Receptors, Antigen, T-Cell, gamma-delta, Hematology, Flow Cytometry, medicine.disease, Minimal residual disease, Lymphoma, Treatment Outcome, Oncology, Splenomegaly, Chain gene, business, Follow-Up Studies, Hepatomegaly, medicine.drug, Epirubicin
Abstract

This study hereby reports the case of a 19-year old boy with a gamma-delta hepatosplenic T-cell lymphoma (HSTCL). Initial therapy consisted of four cycles of the IEV (Ifosphamide, Epirubicin and Etoposide) scheme. Further treatment strategy was then adapted according to minimal residual disease monitoring by immunophenotypic and T-cell receptor gamma chain gene evaluation. The patient remains in complete clinical, immunological and molecular remission and in good clinical conditions 48 months after diagnosis and 40 months after stopping therapy.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results